IRWD — Ironwood Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $589.91m
- $895.78m
- $296.15m
Ironwood Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ironwood Pharmaceuticals Q1 Revenue USD 74.877 Million Vs. IBES Estimate USD 105.8 Million
Ironwood Pharmaceuticals Inc expected to post earnings of 19 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Boeing, Chemours, C3.ai
U.S. STOCKS ON THE MOVE-Voyager Therapeutics, GoodRx Holdings, Tenet Healthcare
Ironwood Pharma tumbles as bowel disease treatment misses secondary goals in trial
Ironwood's bowel disease treatment meets main goal in late-stage trial (updated)
Ironwood says bowel disease treatment meets main goal in late-stage trial
Brief: Ironwood Pharmaceuticals Announces Positive Topline Results From Global Phase III Trial Of Once-Weekly Apraglutide In Adults
U.S. RESEARCH ROUNDUP-Albemarle, Dropbox, Tyler Technologies
Ironwood Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ironwood Pharmaceuticals Q4 Revenue USD 117.553 Million Vs. IBES Estimate USD 117.5 Million
Ironwood Pharmaceuticals Inc expected to post earnings of 21 cents a share - Earnings Preview
Brief: Ironwood Pharmaceuticals Announces FY 2024 Financial Guidance
Brief: Ironwood Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Ironwood Pharmaceuticals - Maintains Full Year 2023 Guidance
Brief: Ironwood Pharmaceuticals Q3 Revenue USD 113.739 Million Vs. IBES Estimate USD 112.9 Million
Brief: Ironwood Pharmaceuticals Presents Positive Final Data From Stars Nutrition, A Phase II Study Of Apraglutide In Short Bowel Syndrome With Intestinal Failure And Colon In Continuity At United European Gastroenterology Week
Brief: Ironwood To Present New Data Reinforcing Impact Of Linaclotide On Functional Constipation In Children And Adolescents At Naspghan Annual Meeting